| U.S. Court Upholds Patent on Plavix June 19, 2007 On Tuesday, U.S. district judge Sidney Stein in Manhattan ruled that the patent on the world’s second best selling drug Plavix, an anti-platelet agent for cardiovascular disease, made by Bristol-Myers Squibb and Sanofi- Aventis is valid until November 2011. Judge Stein found that the Canadian company, Apotex Inc., failed to prove that the patent "is invalid or unenforceable on any of the grounds asserted." Apotex, the largest producer of generic drugs in Canada, has been challenging the patent claim since 2002. In August 2006, Apotex marketed the generic version of Plavix for several months. The judge today ruled that Bristol-Myers Squibb and Sanofi- Aventis "are entitled to permanent injunctive relief and……damages”. Generic drugs are considerably cheaper than brand-name drugs, and often lead to a significant price plunge in the name-brand price. |
News
Cardiovascularweb
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
 | |  | |  |